These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 19575771)

  • 1. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).
    Shindel AW
    J Sex Med; 2009 Jul; 6(7):1794-808; quiz 1793, 1809-10. PubMed ID: 19575771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
    Shindel AW
    J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
    Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
    J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
    Chung E
    J Sex Med; 2010 Apr; 7(4 Pt 1):1321-3. PubMed ID: 20492423
    [No Abstract]   [Full Text] [Related]  

  • 5. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners.
    Teloken P; Mesquita G; Montorsi F; Mulhall J
    J Sex Med; 2009 Jul; 6(7):2032-8. PubMed ID: 19453918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
    Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
    J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penile rehabilitation following radical prostatectomy: predicting success.
    Müller A; Parker M; Waters BW; Flanigan RC; Mulhall JP
    J Sex Med; 2009 Oct; 6(10):2806-12. PubMed ID: 19732314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase type 5 inhibitors facilitate noncontact erections in male rats: site of action in the brain and mechanism of action.
    Sanna F; Succu S; Boi A; Melis MR; Argiolas A
    J Sex Med; 2009 Oct; 6(10):2680-9. PubMed ID: 19678884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.
    Nandipati KC; Raina R; Agarwal A; Zippe CD
    Drugs Aging; 2006; 23(2):101-17. PubMed ID: 16536634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy.
    Furtado TP; Miranda EP; Deveci S; Jenkins L; Narus J; Nelson C; Mulhall JP
    J Sex Med; 2023 Dec; 21(1):29-32. PubMed ID: 37973393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erectile dysfunction.
    Katz A; Katz A
    CMAJ; 2010 Mar; 182(4):381-2. PubMed ID: 20142374
    [No Abstract]   [Full Text] [Related]  

  • 16. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is vardenafil "noninferior" or superior to sildenafil in the management of erectile dysfunction? Revisiting the biochemical, physiological, and clinical evidence.
    Traish A; Kim N
    J Sex Med; 2008 Jul; 5(7):1762-8; discussion 1768-9. PubMed ID: 18221281
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical monograph for drug formulary review: erectile dysfunction agents.
    Campbell HE
    J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
    Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
    Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.